|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Human parathyroid hormone-related peptide(1-40)>> Market Analysis Reports |
Market Analysis Reports of Human parathyroid hormone-related peptide(1-40) |
|
NPS Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... of naturally occurring human glucagon-like peptide 2 (GLP-2), a peptide secreted primarily ... the companys recombinant full-length human parathyroid hormone (rhPTH (1-84)) that is in Phase ... sell products covered by patents relating to the modulation of NMDA ... Asia Pacific Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent ... Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of ... Global Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Region: Trend Forecast and Growth Opportunity Global biosimilars market will reach $113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many ... North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent ... Global Cancer Diagnostics Market 2013 France, Germany, Italy, Japan, Spain, UK, USA Sales Forecasts, Supplier Shares, Competitive Strategies Complete report $32,500. DataPack (test volumes, sales forecasts, supplier shares) $21,100. Summary This comprehensive seven-country report contains 1,200 pages, 450 tables, and presents analysis of the major business opportunities emerging in the cancer ... Teriparatide– Biosimilar Insight, 2022 ... Teriparatide: Overview Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used ... types such as Monoclonal antibodies Peptide Protein Small molecule ... and acquisitions, licensing activities related to the Teriparatide biosimilars ... Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors Product description Parathyroid hormone/parathyroid hormone-related peptide receptor also known as parathyroid hormone 1 receptor (PTH1R) functions as a receptor for parathyroid hormone (PTH ... |